Wayne Paterson

CEO of @Anteris $AVR. 25 years building #healthcare businesses around the world. Passionate about #medtech’s potential for people.

[Wayne Paterson @CEOPaterson]

@MikeASperrazza Love it

[João Cavalcante @JoaoLCavalcante]

@mirvatalasnag @crfheart @AChoiHeart @purviparwani @OKhaliqueMD @ChamsiPash @Sarah_Moharem @drptca @alessia_gimelli @jgranadacrf @triciarawh @fjsawaya Thank you @mirvatalasnag for capturing this. Privileged to be working w/ @HEARTinMagnet on this, and excited to understand the clinical implications #DurAVR flow pattern might have. @CEOPaterson @chrismeduri @azeemlatib @bapat_savrtavr @AnterisTech @SusheelKodaliMD @SCMRorg

[Wayne Paterson @CEOPaterson]

Excited to present to our shareholders at our AGM in Sydney tomorrow and look forward to seeing you there #proudtobeanteris#DurAVR#

[Anteris Technologies @AnterisTech]

Watch this physician panel to hear Drs @MReardon19 , @chrismeduri , and @azeemlatib discuss the design of the DurAVR™ transcatheter heart valve and the paradigm-shifting hemodynamic results from the US Early Feasibility Study (EFS): https://t.co/G20StDcEfW

[Wayne Paterson @CEOPaterson]

Further evidence that DurAVR™ the first in class biomimetic valve built on the Adapt® tissue platform is showing exceptional results due to its novel valve design and superior tissue science whilst maintaining more predictable delivery with a novel BE platform #valvedesign

[Cardiovascular News @CN_publishing]

#PCRLV: @azeemlatib presents insights from the first in man implant of the DurAVR biomimetic TAVI valve (@AnterisTech). He reports that the device had a favourable safety profile, and “outstanding” haemodynamic performance

[Cardiovascular News @CN_publishing]

#PCRLV: @azeemlatib presents insights from the first in man implant of the DurAVR biomimetic TAVI valve (@AnterisTech). He reports that the device had a favourable safety profile, and “outstanding” haemodynamic performance

[Andrea Scotti @AndreaScotti21]

⭐️ FIH & EFS data on DurAVR just presented by @azeemlatib #PCRLV

🎯Balloon-expandable
🎯Commissure-alignment
🎯Long coaptation length
🎯EXCELLENT Hemodynamics

@chrismeduri @AnterisTech @MonteHeart

[Anteris Technologies @AnterisTech]

Last week Stephanie Sellers presented bench testing results from the novel DurAVR™ THV at #TCT2023. DurAVR demonstrated superior hemodynamic performance in Redo-TAVR procedures. Learn more about DurAVR here: https://t.co/qIicm0LAyu

#TAVR #TAVI #innovation #AnterisTech

[Pankaj Garg @HEARTinMagnet]

Is this aortic flow normal?
Two papers will help to understand the pathophysiological aetiology better -
https://t.co/De5cOQVZdo

https://t.co/BQixK3jlqD

Aortic flow MATTERS. 💯

[Wayne Paterson @CEOPaterson]

Great way to end a great week. Meeting with the V2V team to discuss our unique TEER device for mitral repair.Thanks to the Anteris team for all the work that culminated in a great #TCT for #AVR #movingtheconversationforward #proudtobeanteris

[Joe Doyle @Rocket2010]

$AVR one of the unique distinguishing features of #DurAVR is the return of near perfect laminar flow. This impacts on valve durability, performance +. As > evidence emerges this will become a required expectation in valve performance. No other valve achieves this. #TAVR #TCT2023

[Wayne Paterson @CEOPaterson]

Great week at TCT with incredible data being presented by Anteris demonstrating superior MPG's ,superior EOA's and superior DVI's to current therapies. A huge thanks to our team,Physicians and patients. We are moving the conversation forward ! #proudtobeanteris #DurAVR

[Anteris Technologies @AnterisTech]

It's been an exciting day of TAVR data at #TCT2023, with major updates on #TAVR studies! It's clear that valve performance matters. Tune in this afternoon for DurAVR™ THV US EFS discharge data -- moving the conversation forward with paradigm-shifting hemodynamic performance!

[Anteris Technologies @AnterisTech]

Standing room only! At #TCT2023, @chrismeduri presented the latest data from the DurAVR™ THV FIH Study. Remarkable hemodynamic results are holding steady at 6 months and 1 year post-op! More info: https://t.co/qIicm0M8o2

#TAVR #TAVI #clinicaltrial #innovation

[Wayne Paterson @CEOPaterson]

Great presentation today by Dr Latib on our US EFS study. Hemodynamics, EOAs, DVI results are unprecedented. #hemodynamicsmatter #valvedesignmatters #proudtobeanteris

[Chris Meduri, MD MPH @chrismeduri]

DurAVR US EFS results presented @TCTMD by @azeemlatib today

In small annuli patients (mean 22.2):

✔️ safe, easy to use
✔️ no pacemakers
✔️ 93% no/trace, 7% mild PVL

🎯mean EOA 2.36
🎯MPG 7.8
🎯DVI 0.71

This groundbreaking, first biomimetic valve will change AS treatment

[Wayne Paterson @CEOPaterson]

@AnterisTech @tavrkapadia @ClevelandClinic Thanks Dr Kapadia, Dr Krishnaswamy and Dr Puri and your fantastic team for completing 3 more patients. Thanks to the patients as well for participating, great results by a great team. #proudtobeanteris#DurAVR#TCT

[Wayne Paterson @CEOPaterson]

Anteris’ starts US trial for DurAVR transcatheter heart valve
https://t.co/1ta4EgcgZ1 via @MedicalTechMag

[Proactive Australia @proactive_au]

$AVR Anteris Technologies improves US investor access with American Depository Receipt program https://t.co/lhxdBsPc6d @AnterisTech $DDF $AMEUF #AVR #DDF #AMEUF #ASX #ASXNews

[Azeem Latib @azeemlatib]

Incredible teamwork and support by a world-class SH team. We could not do this without our amazing team: @EdwinHoMD @MeiChau3 @m_assafin @AndreaScotti21 @jimmydoolittle @KaraBoothMonte and her research team
@jesusdaiyan @MonteHeart

[Wayne Paterson @CEOPaterson]

@azeemlatib @EdwinHoMD @MeiChau3 @m_assafin @AndreaScotti21 @JimmyDoolittle @jesusdaiyan @MonteHeart Thanks Azeem to you and your team for treating these patients, amazing team, amazing outcomes !